Abstract
Purpose
We aimed to evaluate the role of the chorioallantoic membrane model (CAM) in breast cancer research.
Methods
The following is an overview of the use of the CAM in the field of breast cancer research based on a PubMed literature query.
Results
The CAM is a 3D in vivo model that can be used for the analysis of tumor growth, biology and angiogenesis of primary tumor tissue or tumor cell lines. The CAM model has been used in breast cancer research for drug testing, migration assays and the evaluation of vascularization, amongst others. The CAM model is a valuable method that offers a better imitation of the physiological phenomena compared to 2D or 3D in vitro models.
Conclusion
The CAM model has primarily and successfully been utilized for the assessment of the tumor biology of established breast cancer cell lines. Further, the CAM model is a promising method to analyze patient derived primary tumor material and could be used as a “patient-specific 3D-tumor-therapy-model” for the cost-efficient evaluation of anti-cancer drugs to find the optimal treatment for breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achkar IW, Kader S, Dib SS, Junejo K, Al-Bader SB, Hayat S, Bhagwat AM, Rousset X, Wang Y, Viallet J, Suhre K, Halama A (2020) Metabolic signatures of tumor responses to doxorubicin elucidated by metabolic profiling in ovo. Metabolites. https://doi.org/10.3390/metabo10070268
Agarwal A, Muñoz-Nájar U, Klueh U, Shih S-C, Claffey KP (2004) N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol 164:1683–1696. https://doi.org/10.1016/S0002-9440(10)63727-3
Arnold JM, Gu F, Ambati CR, Rasaily U, Ramirez-Pena E, Joseph R, Manikkam M, San Martin R, Charles C, Pan Y, Chatterjee SS, den Hollander P, Zhang W, Nagi C, Sikora AG, Rowley D, Putluri N, Zhang XH-F, Karanam B, Mani SA, Sreekumar A (2020) UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression. Oncogene 39:3089–3101. https://doi.org/10.1038/s41388-019-0885-4
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32–40. https://doi.org/10.1373/49.1.32
Ausprunk DH, Folkman J (1976) Vascular injury in transplanted tissues. Fine structural changes in tumor, adult, and embryonic blood vessels. Virchows Arch B Cell Pathol 21:31–44
Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093–1102
Banskota S, Gautam J, Regmi SC, Gurung P, Park M-H, Kim SJ, Nam T-G, Jeong B-S, Kim J-A (2016) BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analog, inhibits serotonin-induced angiogenesis and tumor growth through PI3K/NOX pathway. Proc Natl Acad Sci USA 11:e0148133. https://doi.org/10.1371/journal.pone.0148133
Baum O, Hlushchuk R, Forster A, Greiner R, Clézardin P, Zhao Y, Djonov V, Gruber G (2007) Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Int J Oncol 30:325–332
Bharali DJ, Yalcin M, Davis PJ, Mousa SA (2013) Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (lond) 8:1943–1954. https://doi.org/10.2217/nnm.12.200
Boucherit N, Gorvel L, Olive D (2020) 3D tumor models and their use for the testing of immunotherapies. Front Immunol 11:603640. https://doi.org/10.3389/fimmu.2020.603640
Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G, He Y, Li Y, Zheng L, Zhang Q, Li J, Wang L, Qi C (2020) Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/ BAI1 signaling pathway. Angiogenesis 23:325–338. https://doi.org/10.1007/s10456-020-09707-z
Cheang MCU, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA (2015) Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20:474–482. https://doi.org/10.1634/theoncologist.2014-0372
Chen J, Rodriguez JA, Barnett B, Hashimoto N, Tang J, Yoneda T (2003) Bone sialoprotein promotes tumor cell migration in both in vitro and in vivo models. Connect Tissue Res 44(Suppl 1):279–284
Chen J, Zhou Z, Yao Y, Dai J, Zhou D, Wang L, Zhang Q-Q (2018) Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway. J Cell Mol Med 22:4760–4770. https://doi.org/10.1111/jcmm.13727
Chen Z, Tong L-J, Tang B-Y, Liu H-Y, Wang X, Zhang T, Cao X-W, Chen Y, Li H-L, Qian X-H, Xu Y-F, Xie H, Ding J (2019) C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacol Sin 40:823–832. https://doi.org/10.1038/s41401-018-0191-7
Chen MJ, Chiou PP, Lin P, Lin C-M, Siri S, Peck K, Chen TT (2007) Suppression of growth and cancer-induced angiogenesis of aggressive human breast cancer cells (MDA-MB-231) on the chorioallantoic membrane of developing chicken embryos by E-peptide of pro-IGF-I. J Cell Biochem 101:1316–1327. https://doi.org/10.1002/jcb.21254
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18:4465–4472. https://doi.org/10.1158/1078-0432.CCR-12-0286
Chien W, O’Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, Koeffler HP (2011) Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 38:1741–1747. https://doi.org/10.3892/ijo.2011.985
Cimpean AM, Seclaman E, Ceauşu R, Gaje P, Feflea S, Anghel A, Raica M, Ribatti D (2010) VEGF-A/HGF induce Prox-1 expression in the chick embryo chorioallantoic membrane lymphatic vasculature. Clin Exp Med 10:169–172. https://doi.org/10.1007/s10238-009-0085-6
ComŞa Ş, Popescu R, Avram Ş, Ceaușu RA, Cîmpean AM, Raica M (2017) Bevacizumab modulation of the interaction between the MCF-7 cell line and the chick embryo chorioallantoic membrane. In Vivo 31:199–203
ComŞa Ş, CeauȘu A-R, Popescu R, SArb S, CImpean A-M, Raica M (2020) The MSC-MCF-7 duet playing tumor vasculogenesis and angiogenesis onto the chick embryo chorioallantoic membrane. In Vivo 34:3315–3325
Conte C, Moret F, Esposito D, Dal Poggetto G, Avitabile C, Ungaro F, Romanelli A, Laurienzo P, Reddi E, Quaglia F (2019) Biodegradable nanoparticles exposing a short anti-FLT1 peptide as antiangiogenic platform to complement docetaxel anticancer activity. Mater Sci Eng C Mater Biol Appl 102:876–886. https://doi.org/10.1016/j.msec.2019.04.054
Dehelean CA, Feflea S, Molnár J, Zupko I, Soica C (2012) Betulin as an antitumor agent tested in vitro on A431, HeLa and MCF7, and as an angiogenic inhibitor in vivo in the CAM assay. Nat Prod Commun 7:981–985
Du X, Todorov P, Isachenko E, Rahimi G, Mallmann P, Meng Y, Isachenko V (2020) Increasing of malignancy of breast cancer cells after cryopreservation: molecular detection and activation of angiogenesis after CAM-xenotransplantation. BMC Cancer 20:753. https://doi.org/10.1186/s12885-020-07227-z
Dubey P, Shrivastava R, Tripathi C, Jain NK, Tewari BN, Lone M-U-D, Baghel KS, Kumar V, Misra S, Bhadauria S, Bhatt MLB (2014) Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages. Cell Mol Biol 60:10–15
El Gaafary M, Hafner S, Lang SJ, Jin L, Sabry OM, Vogel CV, Vanderwal CD, Syrovets T, Simmet T (2019) A novel polyhalogenated monoterpene induces cell cycle arrest and apoptosis in breast cancer cells. Mar Drugs. https://doi.org/10.3390/md17080437
Feder A-L, Pion E, Troebs J, Lenze U, Prantl L, Htwe MM, Phyo A, Haerteis S, Aung T (2020) Extended analysis of intratumoral heterogeneity of primary osteosarcoma tissue using 3D-in-vivo-tumor-model. Clin Hemorheol Microcirc 76:133–141. https://doi.org/10.3233/CH-209204
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186. https://doi.org/10.1056/NEJM197111182852108
Gandhi M, Groß M, Holler JM, Coggins SA, Patil N, Leupold JH, Munschauer M, Schenone M, Hartigan CR, Allgayer H, Kim B, Diederichs S (2020) The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun 11:3214. https://doi.org/10.1038/s41467-020-17007-9
Gao F, Zhang L, Underhill CB (2002) Promotion of growth of human breast cancer cells MDA231 by human sperm membrane-bound hyaluronidase: an experimental study. Zhonghua Yi Xue Za Zhi 82:207–210
Gao F, Cao M, Wang L (2004) Brain hyaluronan binding protein inhibits tumor growth. Chin Med J (engl) 117:1072–1078
Gao W, Jin K, Lan H, Han N, Cao F, Teng L (2012) FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects. Hepatogastroenterology 59:2543–2547. https://doi.org/10.5754/hge12159
Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam T-G, Jeong B-S, Kim J-A (2016) Tryptophan hydroxylase 1 and 5-HT(7) receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer 15:75. https://doi.org/10.1186/s12943-016-0559-6
Gautam J, Banskota S, Lee H, Lee Y-J, Jeon YH, Kim J-A, Jeong B-S (2018) Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis. Exp Mol Med 50:118. https://doi.org/10.1038/s12276-018-0135-9
Ghiulai R, Avram S, Stoian D, Pavel IZ, Coricovac D, Oprean C, Vlase L, Farcas C, Mioc M, Minda D, Motoc A, Szuhanek C, Danciu C, Soica C, Sima L (2020) Lemon balm extracts prevent breast cancer progression in vitro and in ovo on chorioallantoic membrane assay. Evid Based Complement Alternat Med 2020:6489159. https://doi.org/10.1155/2020/6489159
Guido BC, Ramos LM, Nolasco DO, Nobrega CC, Andrade BYG, Pic-Taylor A, Neto BAD, Corrêa JR (2015) Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features. BMC Cancer 15:283. https://doi.org/10.1186/s12885-015-1274-1
Gunasekaran VP, Nishi K, Sivakumar D, Sivaraman T, Mathan G (2018) Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer. Eur J Pharm Sci 116:2–14. https://doi.org/10.1016/j.ejps.2017.09.019
Guo J, Su F, Yao H, Chen J (2007) Alternatively activated macrophages/mononuclear phagocytes promote growth and invasion of breast cancer cell line SKBR3. Nan Fang Yi Ke Da Xue Xue Bao 27:410–413
Hamed A, Frese M, Elgaafary M, Syrovets T, Sewald N, Simmet T, Shaaban M (2020) Synthesis of novel feruloyl dipeptides with proapoptotic potential against different cancer cell lines. Bioorg Chem 97:103678. https://doi.org/10.1016/j.bioorg.2020.103678
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F (2019) Breast Cancer Nat Rev Dis Primers 5:66. https://doi.org/10.1038/s41572-019-0111-2
Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, Braems G, van den Broecke R, Cocquyt V, Gespach C, Bracke M, de Wever O (2013) Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer 133:843–854. https://doi.org/10.1002/ijc.28079
Huang Y, Zhao K, Hu Y, Zhou Y, Luo X, Li X, Wei L, Li Z, You Q, Guo Q, Lu N (2016) Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/β-catenin pathway. Mol Carcinog 55:1598–1612. https://doi.org/10.1002/mc.22412
Huang Y, Fang J, Lu W, Wang Z, Wang Q, Hou Y, Jiang X, Reizes O, Lathia J, Nussinov R, Eng C, Cheng F (2019) A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chem Biol 26:1143-1158.e6. https://doi.org/10.1016/j.chembiol.2019.05.004
Huang KF, Huang XP, Xiao GQ, Yang HY, Lin JS, Diao Y (2014) Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway. Biomed Pharmacother 68:455–461. https://doi.org/10.1016/j.biopha.2014.03.005
Huwiler A, Bourquin F, Kotelevets N, Pastukhov O, Capitani G, Grütter MG, Zangemeister-Wittke U (2011) A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. PLoS ONE 6:e22436. https://doi.org/10.1371/journal.pone.0022436
Hwang WC, Kang DW, Kang Y, Jang Y, Kim J-A, Min DS (2020) Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells. Biol Res 53:34. https://doi.org/10.1186/s40659-020-00294-3
Jiang Y, Xie K-P, Huo H-N, Wang L-M, Zou W, Xie M-J (2013) Inhibitory effect of luteolin on the angiogenesis of chick chorioallantoic membrane and invasion of breast cancer cells via downregulation of AEG-1 and MMP-2. Sheng Li Xue Bao 65:513–518
Jiang K, Liu P, Xu H, Liang D, Fang K, Du S, Cheng W, Ye L, Liu T, Zhang X, Gong P, Shao S, Wang Y, Meng S (2020) SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis. Oncogene 39:5015–5030. https://doi.org/10.1038/s41388-020-1356-7
Jing M, Bi X-J, Yao X-M, Cai F, Liu J-J, Fu M, Kong L, Liu X-Z, Zhang L, He S-Y, Jia L-Q, Li X-T (2020) Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis. Drug Dev Ind Pharm 46:621–634. https://doi.org/10.1080/03639045.2020.1742145
Joimel U, Gest C, Soria J, Pritchard L-L, Alexandre J, Laurent M, Blot E, Cazin L, Vannier J-P, Varin R, Li H, Soria C (2010) Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. BMC Cancer 10:375. https://doi.org/10.1186/1471-2407-10-375
Kang Y, Regmi SC, Kim MY, Banskota S, Gautam J, Kim DH, Kim J-A (2015) Anti-angiogenic activity of macrolactin A and its succinyl derivative is mediated through inhibition of class I PI3K activity and its signaling. Arch Pharm Res 38:249–260. https://doi.org/10.1007/s12272-014-0535-x
Karia P, Patel KV, Rathod SSP (2018) Breast cancer amelioration by Butea monosperma in-vitro and in-vivo. J Ethnopharmacol 217:54–62. https://doi.org/10.1016/j.jep.2017.12.026
Kauffmann P, Troeltzsch M, Cordesmeyer R, Heidekrueger PI, Schliephake H, Canis M, Wolff HA, Rave-Fraenk M, Stroebel P, Kehrer A, Prantl L, Aung T (2017) Presentation of a variation of the chorioallantoic membrane set up as a potential model for individual therapy for squamous cell carcinoma of the oropharynx. Clin Hemorheol Microcirc 67:453–457. https://doi.org/10.3233/CH-179226
Kauffmann P, Troeltzsch M, Brockmeyer P, Bohnenberger H, Heidekrüger PI, Manzke M, Canis M, Gaayathiri S, Schliephake H, Prantl L, Aung T (2018) First experience of chick chorioallantoic membrane (CAM) assay in the clinical work flow with oral squamous cell carcinoma patients. Clin Hemorheol Microcirc 70:487–494. https://doi.org/10.3233/CH-189315
Kim J-A, Cho KB, Kim MR, Park BC, Kim SK, Lee MY, Kang KW (2008) Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells. Cancer Lett 268:225–232. https://doi.org/10.1016/j.canlet.2008.03.050
Kim J-A, Kim MR, Kim O, Phuong NTT, Yun J, Oh WK, Bae K, Kang KW (2012) Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition. Food Chem Toxicol 50:3625–3634. https://doi.org/10.1016/j.fct.2012.07.027
Kim MR, Choi HS, Yang JW, Park BC, Kim J-A, Kang KW (2009) Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression. Mol Cancer Ther 8:2163–2171. https://doi.org/10.1158/1535-7163.MCT-08-1061
Kim JW, Gautam J, Kim JE, Kim J-A, Kang KW (2019) Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. Oncol Lett 17:3981–3989. https://doi.org/10.3892/ol.2019.10059
Kimlin LC, Casagrande G, Virador VM (2013) In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 52:167–182. https://doi.org/10.1002/mc.21844
Kohl C, Aung T, Haerteis S, Papathemelis T (2021) Assessment of breast cancer primary tumor material in a 3D in vivo model. Clin Hemorheol Microcirc 79:157–166. https://doi.org/10.3233/ch-219113
Lang SJ, Schmiech M, Hafner S, Paetz C, Steinborn C, Huber R, Gaafary ME, Werner K, Schmidt CQ, Syrovets T, Simmet T (2019) Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients. Phytomedicine 62:152962. https://doi.org/10.1016/j.phymed.2019.152962
Lang SJ, Schmiech M, Hafner S, Paetz C, Werner K, El Gaafary M, Schmidt CQ, Syrovets T, Simmet T (2020) Chrysosplenol d, a flavonol from artemisia annua, induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Int J Mol Sci. https://doi.org/10.3390/ijms21114090
Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O’Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM (2018) Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Res 20:140. https://doi.org/10.1186/s13058-018-1064-1
Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A (2014) The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells. BMC Cancer 14:158. https://doi.org/10.1186/1471-2407-14-158
Lenkavska L, Blascakova L, Jurasekova Z, Macajova M, Bilcik B, Cavarga I, Miskovsky P, Huntosova V (2019) Benefits of hypericin transport and delivery by low- and high-density lipoproteins to cancer cells: from in vitro to ex ovo. Photodiagnosis Photodyn Ther 25:214–224. https://doi.org/10.1016/j.pdpdt.2018.12.013
Lester RD, Jo M, Montel V, Takimoto S, Gonias SL (2007) uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 178:425–436. https://doi.org/10.1083/jcb.200701092
Li J, Li F, Wang H, Wang X, Jiang Y, Li D (2012) Wortmannin reduces metastasis and angiogenesis of human breast cancer cells via nuclear factor-κB-dependent matrix metalloproteinase-9 and interleukin-8 pathways. J Int Med Res 40:867–876. https://doi.org/10.1177/147323001204000305
Martowicz A, Spizzo G, Gastl G, Untergasser G (2012) Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12:501. https://doi.org/10.1186/1471-2407-12-501
Mira E, Lacalle RA, Gómez-Moutón C, Leonardo E, Mañes S (2002) Quantitative determination of tumor cell intravasation in a real-time polymerase chain reaction-based assay. Clin Exp Metastasis 19:313–318. https://doi.org/10.1023/a:1015563031769
Harbeck N, Würstlein R (2020) Mammakarzinom. therapietabellen, 1st edn. mgo fachverlage
Ngan E, Stoletov K, Smith HW, Common J, Muller WJ, Lewis JD, Siegel PM (2017) LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis. Nat Commun 8:15059. https://doi.org/10.1038/ncomms15059
Nguyen M, Shing Y, Folkman J (1994) Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47:31–40. https://doi.org/10.1006/mvre.1994.1003
Nienhuis HH, Arjaans M, Timmer-Bosscha H, de Vries EGE, Schröder CP (2015) Human stromal cells are required for an anti-breast cancer effect of zoledronic acid. Oncotarget 6:24436–24447
Nowak-Sliwinska P, Ballini J-P, Wagnières G, van den Bergh H (2010) Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res 79:21–28. https://doi.org/10.1016/j.mvr.2009.10.004
Oh SJ, Kim O, Lee JS, Kim J-A, Kim MR, Choi HS, Shim J-H, Kang KW, Kim YC (2010) Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food Chem Toxicol 48:3227–3234. https://doi.org/10.1016/j.fct.2010.08.028
Oliveira C, Granja S, Neves NM, Reis RL, Baltazar F, Silva TH, Martins A (2019) Fucoidan from Fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo. Carbohydr Polym 223:115034. https://doi.org/10.1016/j.carbpol.2019.115034
Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M (2012) Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res 32:45–52
Park BC, Park S-Y, Lee J-S, Mousa SA, Kim JT, Kwak M-K, Kang KW, Lee E-S, Choi HG, Yong CS, Kim J-A (2009) The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol 50:123–131. https://doi.org/10.1016/j.vph.2008.11.006
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167. https://doi.org/10.1200/JCO.2008.18.1370
Pathak P, Shukla PK, Kumar V, Kumar A, Verma A (2018) Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity. Inflammopharmacology 26:1441–1453. https://doi.org/10.1007/s10787-018-0471-3
Pathuri G, Thorpe JE, Disch BC, Bailey-Downs LC, Ihnat MA, Gali H (2013) Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor. Bioorg Med Chem Lett 23:3561–3564. https://doi.org/10.1016/j.bmcl.2013.04.031
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093
Pinto MT, Ribeiro AS, Conde I, Carvalho R, Paredes J (2020) The chick chorioallantoic membrane model: a new in vivo tool to evaluate breast cancer stem cell activity. Int J Mol Sci. https://doi.org/10.3390/ijms22010334
Pion E, Asam C, Feder A-L, Felthaus O, Heidekrueger PI, Prantl L, Haerteis S, Aung T (2021) Laser speckle contrast analysis (LASCA) technology for the semiquantitative measurement of angiogenesis in in-ovo-tumor-model. Microvasc Res 133:104072. https://doi.org/10.1016/j.mvr.2020.104072
Ponce ML, Hibino S, Lebioda AM, Mochizuki M, Nomizu M, Kleinman HK (2003) Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res 63:5060–5064
Prudent R, Vassal-Stermann É, Nguyen C-H, Mollaret M, Viallet J, Desroches-Castan A, Martinez A, Barette C, Pillet C, Valdameri G, Soleilhac E, Di Pietro A, Feige J-J, Billaud M, Florent J-C, Lafanechère L (2013) Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities. Br J Pharmacol 168:673–685. https://doi.org/10.1111/j.1476-5381.2012.02230.x
Pund S, Thakur R, More U, Joshi A (2014) Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy. Colloids Surf B Biointerfaces 120:110–117. https://doi.org/10.1016/j.colsurfb.2014.05.016
Qi C, Zhou Q, Li B, Yang Y, Cao L, Ye Y, Li J, Ding Y, Wang H, Wang J, He X, Zhang Q, Lan T, Lee KKH, Li W, Song X, Zhou J, Yang X, Wang L (2014) Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget 5:9966–9979
Quail DF, Walsh LA, Zhang G, Findlay SD, Moreno J, Fung L, Ablack A, Lewis JD, Done SJ, Hess DA, Postovit L-M (2012) Embryonic protein nodal promotes breast cancer vascularization. Cancer Res 72:3851–3863. https://doi.org/10.1158/0008-5472.CAN-11-3951
Rezaei M, Martins Cavaco AC, Stehling M, Nottebaum A, Brockhaus K, Caliandro MF, Schelhaas S, Schmalbein F, Vestweber D, Eble JA (2020) Extracellular vesicle transfer from endothelial cells drives VE-cadherin expression in breast cancer cells thereby causing heterotypic cell contacts. Cancers (basel). https://doi.org/10.3390/cancers12082138
Ribatti D (2014) The chick embryo chorioallantoic membrane as a model for tumor biology. Exp Cell Res 328:314–324. https://doi.org/10.1016/j.yexcr.2014.06.010
Ribatti D (2016) The chick embryo chorioallantoic membrane (CAM) a multifaceted experimental model. Mech Dev 141:70–77. https://doi.org/10.1016/j.mod.2016.05.003
Schexnayder C, Broussard K, Onuaguluchi D, Poché A, Ismail M, McAtee L, Llopis S, Keizerweerd A, McFerrin H, Williams C (2018) Metformin Inhibits migration and invasion by suppressing ROS production and COX2 expression in MDA-MB-231 breast cancer cells. Int J Mol Sci. https://doi.org/10.3390/ijms19113692
Schmiech M, Lang SJ, Ulrich J, Werner K, Rashan LJ, Syrovets T, Simmet T (2019) Comparative investigation of frankincense nutraceuticals: correlation of boswellic and lupeolic acid contents with cytokine release inhibition and toxicity against triple-negative breast cancer cells. Nutrients. https://doi.org/10.3390/nu11102341
Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KHB, Chinnathambi A, Alahmadi TA, Alharbi SA, Koh APF, Arfuso F, Huang RY-J, Lim LHK, Sethi G, Kumar AP (2018) Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis. Front Pharmacol 9:1294. https://doi.org/10.3389/fphar.2018.01294
Shimo T, Nakanishi T, Nishida T, Asano M, Sasaki A, Kanyama M, Kuboki T, Matsumura T, Takigawa M (2001) Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncology 61:315–322. https://doi.org/10.1159/000055339
Shrivastava R, Trivedi S, Singh PK, Asif M, Chourasia MK, Khanna A, Bhadauria S (2018) Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochem Biophys Res Commun 503:677–683. https://doi.org/10.1016/j.bbrc.2018.06.060
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. https://doi.org/10.1073/pnas.191367098
de Spiegeleer B, Verbeke F, D’Hondt M, Hendrix AN, van de Wiele C, Burvenich C, Peremans K, de Wever O, Bracke M, Wynendaele E (2015) The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro. PLoS ONE 10:e0119471. https://doi.org/10.1371/journal.pone.0119471
Strick DM, Waycaster RL, Montani JP, Gay WJ, Adair TH (1991) Morphometric measurements of chorioallantoic membrane vascularity: effects of hypoxia and hyperoxia. Am J Physiol 260:H1385–H1389. https://doi.org/10.1152/ajpheart.1991.260.4.H1385
Sun H, Jia J, Wang X, Ma B, Di L, Song G, Ren J (2013) CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. Clin Transl Oncol 15:46–54. https://doi.org/10.1007/s12094-012-0891-2
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660
Teruszkin Balassiano I, Alves De Paulo S, Henriques Silva N, Curié Cabral M, dada Gloria Costa Carvalho M (2001) Metastatic potential of MDA435 and Hep2 cell lines in chorioallantoic membrane (CAM) model. Oncol Rep 8:431–433
Thuy Phuong NT, Kim JW, Kim J-A, Jeon JS, Lee J-Y, Xu WJ, Yang JW, Kim SK, Kang KW (2017) Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer. Oncotarget 8:71054–71069
Troebs J, Asam C, Pion E, Prantl L, Aung T, Haerteis S (2020) 3D monitoring of tumor volume in an in vivo model. Clin Hemorheol Microcirc 76:123–131. https://doi.org/10.3233/CH-209216
Turtoi A, Blomme A, Bellahcène A, Gilles C, Hennequière V, Peixoto P, Bianchi E, Noel A, de Pauw E, Lifrange E, Delvenne P, Castronovo V (2013) Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res 73:5438–5448. https://doi.org/10.1158/0008-5472.CAN-13-1142
Veiseh M, Kwon DH, Borowsky AD, Tolg C, Leong HS, Lewis JD, Turley EA, Bissell MJ (2014) Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset. Proc Natl Acad Sci USA 111:E1731–E1739. https://doi.org/10.1073/pnas.1402383111
Vellanki SH, Cruz RGB, Richards CE, Smith YE, Hudson L, Jahns H, Hopkins AM (2019a) Antibiotic tetrocarcin-A down-regulates JAM-A, IAPs and induces apoptosis in triple-negative breast cancer models. Anticancer Res 39:1197–1204
Vellanki SH, Cruz RGB, Jahns H, Hudson L, Sette G, Eramo A, Hopkins AM (2019b) Natural compound Tetrocarcin-A downregulates junctional adhesion molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. Cancer Lett 440–441:23–34. https://doi.org/10.1016/j.canlet.2018.09.032
Vilaça N, Bertão AR, Prasetyanto EA, Granja S, Costa M, Fernandes R, Figueiredo F, Fonseca AM, de Cola L, Baltazar F, Neves IC (2021) Surface functionalization of zeolite-based drug delivery systems enhances their antitumoral activity in vivo. Mater Sci Eng C Mater Biol Appl 120:111721. https://doi.org/10.1016/j.msec.2020.111721
Wittig R, Rosenholm JM, von Haartman E, Hemming J, Genze F, Bergman L, Simmet T, Lindén M, Sahlgren C (2014) Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer. Nanomedicine (lond) 9:971–987. https://doi.org/10.2217/nnm.13.62
Xu Y, Wang C, Chen X, Li Y, Bian W, Yao C (2020) San huang decoction targets aurora kinase A to inhibit tumor angiogenesis in breast cancer. Integr Cancer Ther 19:1534735420983463. https://doi.org/10.1177/1534735420983463
Yamada KM, Cukierman E (2007) Modeling tissue morphogenesis and cancer in 3D. Cell 130:601–610. https://doi.org/10.1016/j.cell.2007.08.006
Yoon J-H, Yoon H-E, Kim O, Kim SK, Ahn S-G, Kang KW (2012) The enhanced anti-cancer effect of hexenyl ester of 5-aminolaevulinic acid photodynamic therapy in adriamycin-resistant compared to non-resistant breast cancer cells. Lasers Surg Med 44:76–86. https://doi.org/10.1002/lsm.21154
Yousefnia S, Ghaedi K, Seyed Forootan F, Nasr Esfahani MH (2019) Characterization of the stemness potency of mammospheres isolated from the breast cancer cell lines. Tumour Biol 41:1010428319869101. https://doi.org/10.1177/1010428319869101
Zhang Z, Yang J, Lu J, Lin J, Zeng S, Luo Q (2008) Fluorescence imaging to assess the matrix metalloproteinase activity and its inhibitor in vivo. J Biomed Opt 13:11006. https://doi.org/10.1117/1.2830659
Zhao SG, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence TS, Pierce LJ, Feng FY (2015) Development and validation of a novel platform-independent metastasis signature in human breast cancer. PLoS ONE 10:e0126631. https://doi.org/10.1371/journal.pone.0126631
Zhou Q, Nakada MT, Arnold C, Shieh KY, Markland FSJR (1999) Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 3:259–269. https://doi.org/10.1023/a:1009059210733
Zuo Z, Syrovets T, Genze F, Abaei A, Ma G, Simmet T, Rasche V (2015) High-resolution MRI analysis of breast cancer xenograft on the chick chorioallantoic membrane. NMR Biomed 28:440–447. https://doi.org/10.1002/nbm.3270
Zuo Z, Syrovets T, Wu Y, Hafner S, Vernikouskaya I, Liu W, Ma G, Weil T, Simmet T, Rasche V (2017) The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds. Sci Rep 7:46690. https://doi.org/10.1038/srep46690
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Cynthia Kohl. The first draft of the manuscript was written by Cynthia Kohl and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kohl, C., Aung, T., Haerteis, S. et al. The 3D in vivo chorioallantoic membrane model and its role in breast cancer research. J Cancer Res Clin Oncol 148, 1033–1043 (2022). https://doi.org/10.1007/s00432-022-03936-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-03936-z